MULTICENTER STUDY OF SAFETY AND EFFICACY NIVOLUMAB AT THE FIXED DOSE 40 MG (NIVO40) IN COMBINATION WITH CHEMO-IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL)статья

Статья опубликована в журнале из списка Web of Science и/или Scopus